PMV Pharmaceuticals Inc
PMVP
Health Care
2
exclusion reasons
1 theme
PMV Pharmaceuticals Inc is screened out under 2 exclusion reasons spanning 1 issue category.
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. It is a statement of values.
PMV Pharmaceuticals Inc. is a clinical-stage oncology company developing small molecule therapies targeting p53 mutations. As a pharmaceutical developer, its research pipeline necessitates preclinical testing, which typically involves animal models. The company’s lead candidate, PC14586, is in clinical trials following standard preclinical development, a process that relies on animal testing for initial safety and efficacy data.
While the provided evidence does not detail PMV Pharmaceuticals' specific animal testing protocols, the broader pharmaceutical industry's standard practice is relevant. Preclinical testing for novel chemical entities, especially in oncology, is conducted in animal models as required by global regulatory authorities like the FDA for Investigational New Applications (INDs). The absence of a public commitment to alternative testing methods or a clear policy on animal welfare in its R&D indicates the company follows this conventional, animal-dependent pathway.
This exclusion is based on the company's operational category as a pharmaceutical developer, where animal testing is an inherent and material component of the drug discovery process. Specific evidence of the company's testing practices or a commitment to alternatives was not found in the provided materials.
PMV Pharmaceuticals is a clinical-stage oncology company whose drug development pipeline requires animal testing as a standard component of preclinical research. The company’s public filings consistently reference “animal studies” as a necessary step for assessing the safety and efficacy of its product candidates prior to human clinical trials. This reliance on animal models is an inherent and material part of its business model for bringing new cancer therapies to market.
While the U.S. Food and Drug Administration has announced plans to phase out animal testing requirements for certain drug classes, such as monoclonal antibodies, these reforms are not yet fully implemented and do not yet apply broadly to all novel therapeutic candidates. As a preclinical and clinical-stage biopharmaceutical company, PMV Pharmaceuticals remains subject to existing regulatory frameworks that currently necessitate animal data. There is no public evidence that the company is pursuing or employing non-animal testing methods as a primary alternative for its core research programs.
Research Sources
9 organizations
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.